Sage Therapeutics (SAGE) Set to Announce Quarterly Earnings on Thursday

Sage Therapeutics (NASDAQ:SAGE) is set to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company had revenue of $77.97 million for the quarter, compared to analysts’ expectations of $60.15 million. During the same quarter in the previous year, the company posted ($2.47) earnings per share. The business’s revenue for the quarter was up 2621.5% compared to the same quarter last year. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Sage Therapeutics Price Performance

Shares of NASDAQ:SAGE opened at $12.95 on Wednesday. Sage Therapeutics has a 12 month low of $10.92 and a 12 month high of $59.99. The stock has a market cap of $778.42 million, a price-to-earnings ratio of -1.43 and a beta of 0.86. The stock’s 50 day moving average price is $19.22 and its 200 day moving average price is $20.78.

Analysts Set New Price Targets

Several brokerages recently commented on SAGE. HC Wainwright reissued a “neutral” rating and set a $28.00 target price on shares of Sage Therapeutics in a report on Wednesday, April 17th. Wedbush reissued a “neutral” rating and set a $24.00 target price on shares of Sage Therapeutics in a report on Wednesday, April 17th. TD Cowen dropped their target price on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Scotiabank dropped their target price on Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating on the stock in a report on Thursday, April 18th. Finally, Royal Bank of Canada boosted their target price on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a report on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $39.28.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.